Biologic agents and innovative interventional approaches in the management of systemic lupus erythematosus

Vibeke Strand, V Strand
Current opinion in rheumatology · 1999 · vol. 11(5) , pp. 330–340 · doi:10.1097/00002281-199909000-00002 · PMID:10503651 · W1998135902
Review OA: closed CC0
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-10-12 ⓘ

This review examines biologic agents and innovative interventional approaches for systemic lupus erythematosus, including immunomodulators and gene therapy, while emphasizing the need for international consensus on clinical trial methodology.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-12 · read from full text ⓘ

This review examines the potential of biologic agents and innovative interventional approaches for managing systemic lupus erythematosus, a disease characterized by variable courses of exacerbations and remissions. The authors discuss various immunomodulatory strategies targeting T cell activation, antibody production, complement activation, and cytokine modulation, alongside experimental treatments like gene therapy and stem cell transplantation. Additionally, the paper evaluates specific pharmaceuticals such as thalidomide, mycophenolate mofetil, and hormonal agents including selective estrogen receptor modulators and prolactin inhibitors. The authors note that active participation in clinical trials to establish international consensus on methodology is crucial for developing these therapies. Relevance to endometriosis: The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Systemic lupus erythematosus (SLE) is a difficult disease to study, having a variable disease course characterized by exacerbations and remissions. A variety of biologic agents are under investigation as potential treatments for SLE. These products are designed to specifically interfere with the following immunologic processes: T cell activation/T cell-B cell collaboration, production of anti-double-stranded DNA antibodies, deposition of anti-double-stranded DNA antibody complexes, complement activation, and immune complex deposition and cytokine activation and modulation. More aggressive interventions include gene therapy and stem cell transplantation. Immunomodulatory agents recently examined in patients with SLE include: thalidomide, AS101, 2' chlordeoxyadenosine, mycophenolate mofetil, and bindarit. Additional innovative pharmaceutical treatments include the mild androgen dehydroepiandrosterone, selective estrogen receptor modulators, and the prolactin inhibitor, bromocriptine. A variety of these biologic and pharmaceutical agents offer promise as potential therapies. Active participation in clinical trial efforts to develop international consensus regarding trial methodology and outcome measures are crucial to the development of these innovative therapies.
Full text 1,405 characters · extracted from oa-doi-fallback · click to expand
Biologic agents and innovative interventional approaches in the management of systemic lupus erythematosus - Vibeke Strand Systemic lupus erythematosus (SLE) is a difficult disease to study, having a variable disease course characterized by exacerbations and remissions. A variety of biologic agents are under investigation as potential treatments for SLE. These products are designed to specifically interfere with the following immuno-logic processes: T cell activation/T cell—B cell collaboration, production of anti-double-stranded DMA antibodies, deposition of anti-double-stranded DMA antibody complexes, complement activation, and immune complex deposition and cytokine activation and modulation. More aggressive interventions include gene therapy and stem cell transplantation. Immunomodulatory agents recently examined in patients with SLE include: thalidomide, AS101, 2' chlordeoxyadenosine, mycophenolate mofetil, and bindarit. Additional innovative pharmaceutical treatments include the mild androgen dehydroepiandrosterone, selective estrogen receptor modulators, and the prolactin inhibitor, bromocriptine. A variety of these biologic and pharmaceutical agents offer promise as potential therapies. Active participation in clinical trial efforts to develop international consensus regarding trial methodology and outcome measures are crucial to the development of these innovative therapies.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

Biological Products Genetic Therapy Lupus Erythematosus, Systemic Animals Biological Products Humans Lupus Erythematosus, Systemic Lupus Erythematosus, Systemic

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (48)

Source provenance

openalex
last seen: 2026-05-11T06:39:27.580236+00:00
pubmed
last seen: 2026-10-08T20:59:07.345995+00:00
unpaywall
last seen: 2026-11-08T06:46:05.892536+00:00
License: CC0 · commercial use OK